AcademyHealth’s Michael E. Gluck authors the next in the IVI and Health Affairs blog series. He describes historical public efforts to implement HTA and how it “intersects with all of the major challenges facing US health care: cost, quality, access, equity, social determinants, and the tensions between the country’s dual commitments to innovation and health [...]
In a new post in our ongoing blog series with Health Affairs, ICER's Sarah Emond discusses the challenge of achieving a "grand bargain" in which fair prices and fair access provide optimal benefits to both patients and the health system. At the root, she argues, is the different and sometimes-conflicting perspectives, objectives, and incentives of the [...]
The Health Affairs series continues with a post by Amol Navathe, Risa Lavizzo-Mourey and Joshua Laio examining how fee for service and risk-based payments fuel inequities and four ways we can set an explicit intention to use payments to eradicate inequities. The authors’ four recommendations: Form diverse coalitions with shared principles focused on payment Create [...]
Our second post in the Health Affairs blog series explores how value assessment can bridge the gap between healthcare consumption and payment decisions. Mark Linthicum, Darius Lakdawalla, and Chuck Phelps discuss emerging methods to capture scientific spillover, patients’ lived experience, and risk. Read the full blog post here. The Innovation and Value Initiative [...]
We begin our Health Affairs blog series with the Global Liver Institute’s Donna Cryer sharing insights on how the pandemic has altered our views about how we measure value and how it influences access to quality care. Donna offers three axioms for value assessment: 1) We are all connected; 2) We are all essential; [...]
Author: Rick Chapman, PhD, Chief Science Officer In the context of value assessment, what does patient representativeness mean? A new infographic from IVI, "Value assessment should serve diverse populations and the organizations that provide their care," shows the wide-ranging breadth of factors that comprise patient representativeness. IVI endeavors to fully integrate the patient experience [...]
Over the summer, we sat down with Stephanie Marshall, Director of Advocacy from The Assistance Fund to learn more about the organization and their priorities for the future of value assessment. Tell us a little about your organization. The Assistance Fund (TAF) is an independent 501(c)3 patient assistance organization. We help [...]
Jennifer Bright, Executive Director, Innovation and Value Initiative, issued the following statement on Biden Administration and Congressional Democrats drug pricing proposals. "While exercising government levers to address drug pricing and pricing transparency are needed, the current proposals miss the mark on real solutions to improve affordability and to understand whether healthcare spending actually delivers the [...]
IVI had a chance to sit down with Anna Hyde, Director of Patient Advocacy at the Arthritis Foundation to discuss the organization's goals and how they are getting involved with value assessment. Tell us a little bit about the Arthritis Foundation and its mission and goals. The Arthritis Foundation is boldly [...]
Author: Rick Chapman, PhD, Chief Science Officer, IVI How do we ensure that the data and methods used for value assessment adequately account for the diversity of patients and the urgent need to correct inequities in the health care system – and society in general? Without explicit attention to these issues, health technology assessment [...]
